PL3085383T3 - Kompozycja farmaceutyczna zawierająca erytropoietynę i ceftriakson oraz jej wykorzystanie w wytwarzania leku do leczenia choroby parkinsona - Google Patents
Kompozycja farmaceutyczna zawierająca erytropoietynę i ceftriakson oraz jej wykorzystanie w wytwarzania leku do leczenia choroby parkinsonaInfo
- Publication number
- PL3085383T3 PL3085383T3 PL16166502T PL16166502T PL3085383T3 PL 3085383 T3 PL3085383 T3 PL 3085383T3 PL 16166502 T PL16166502 T PL 16166502T PL 16166502 T PL16166502 T PL 16166502T PL 3085383 T3 PL3085383 T3 PL 3085383T3
- Authority
- PL
- Poland
- Prior art keywords
- ceftriaxone
- erythropoietin
- parkinson
- medicament
- manufacture
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title 1
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 title 1
- 229960004755 ceftriaxone Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104112897A TWI558410B (zh) | 2015-04-22 | 2015-04-22 | 使用一包含有頭孢曲松與紅血球生成素的組合來治療和／或預防巴金森氏症失智 |
| EP16166502.1A EP3085383B1 (en) | 2015-04-22 | 2016-04-21 | A pharmaceutical composition comprising erythropoietin and ceftriaxone and a use thereof in the manufacture of a medicament for the treatment of parkinson's disease dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3085383T3 true PL3085383T3 (pl) | 2019-06-28 |
Family
ID=55808435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16166502T PL3085383T3 (pl) | 2015-04-22 | 2016-04-21 | Kompozycja farmaceutyczna zawierająca erytropoietynę i ceftriakson oraz jej wykorzystanie w wytwarzania leku do leczenia choroby parkinsona |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160310571A1 (pl) |
| EP (1) | EP3085383B1 (pl) |
| JP (1) | JP6298490B2 (pl) |
| KR (1) | KR101971318B1 (pl) |
| CN (1) | CN106177913A (pl) |
| AU (1) | AU2016202491B2 (pl) |
| ES (1) | ES2714123T3 (pl) |
| PL (1) | PL3085383T3 (pl) |
| TR (1) | TR201902863T4 (pl) |
| TW (1) | TWI558410B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI644673B (zh) * | 2017-07-27 | 2018-12-21 | 百朗克股份有限公司 | 頭孢曲松的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| TW201345529A (zh) * | 2012-05-01 | 2013-11-16 | Univ Chung Shan Medical | 使用頭孢曲松來治療和／或預防巴金森氏症失智 |
| CN103417547B (zh) * | 2012-05-16 | 2015-01-14 | 中山医学大学 | 用头孢曲松制备治疗和/或预防帕金森氏症失智的医药品的用途 |
| CN102895654B (zh) * | 2012-09-28 | 2014-07-02 | 上海交通大学医学院附属新华医院 | 促红细胞生成素在制备治帕金森病运动并发症药物中的应用 |
-
2015
- 2015-04-22 TW TW104112897A patent/TWI558410B/zh active
- 2015-06-15 CN CN201510329560.6A patent/CN106177913A/zh active Pending
-
2016
- 2016-04-20 JP JP2016084781A patent/JP6298490B2/ja active Active
- 2016-04-20 AU AU2016202491A patent/AU2016202491B2/en active Active
- 2016-04-21 KR KR1020160048504A patent/KR101971318B1/ko active Active
- 2016-04-21 US US15/135,456 patent/US20160310571A1/en not_active Abandoned
- 2016-04-21 ES ES16166502T patent/ES2714123T3/es active Active
- 2016-04-21 TR TR2019/02863T patent/TR201902863T4/tr unknown
- 2016-04-21 EP EP16166502.1A patent/EP3085383B1/en active Active
- 2016-04-21 PL PL16166502T patent/PL3085383T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160125906A (ko) | 2016-11-01 |
| ES2714123T3 (es) | 2019-05-27 |
| TWI558410B (zh) | 2016-11-21 |
| CN106177913A (zh) | 2016-12-07 |
| EP3085383B1 (en) | 2018-11-28 |
| EP3085383A1 (en) | 2016-10-26 |
| JP2016204375A (ja) | 2016-12-08 |
| TW201637664A (zh) | 2016-11-01 |
| AU2016202491B2 (en) | 2017-04-27 |
| KR101971318B1 (ko) | 2019-08-13 |
| AU2016202491A1 (en) | 2016-11-10 |
| TR201902863T4 (tr) | 2019-06-21 |
| JP6298490B2 (ja) | 2018-03-20 |
| US20160310571A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2023010I1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
| IL253195B (en) | Pharmaceutical preparations containing synthetic glycans for use in the treatment of diseases of the digestive system and methods and methods for their preparation | |
| PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
| IL256085B (en) | A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment | |
| IL237369A0 (en) | Methods for treating Alzheimer's disease and pharmaceutical compositions thereof | |
| EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
| IL232764A (en) | Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease | |
| LT3347002T (lt) | Alzheimerio ligos gydymas tam tikroje pacientų populiacijoje | |
| PT3302454T (pt) | Composições para utilização no tratamento da doença de parkinson e distúrbios associados | |
| HUE056265T2 (hu) | Igmezin Alzheimer-kór kezelésében történõ alkalmazásra | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| IL264040A (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| IL274203A (en) | A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease | |
| EP3162377A4 (en) | Use of -asarone in preparing drugs for preventing and treating alzheimer's disease | |
| IL268131A (en) | A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease | |
| PL3085383T3 (pl) | Kompozycja farmaceutyczna zawierająca erytropoietynę i ceftriakson oraz jej wykorzystanie w wytwarzania leku do leczenia choroby parkinsona | |
| EP3458058C0 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | |
| IL254766A0 (en) | A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome | |
| SMT202100070T1 (it) | Complesso e composizioni per il trattamento di affezioni oculari e cutanee | |
| GB201410869D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| HK40097673A (zh) | ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 | |
| AU2017904825A0 (en) | Treatment of alzheimer's disease with a multifunctional drug |